Fluidigm Corporation (FLDM) is an unconventional investment opportunity in the genomic technology space as the company is not yet profitable, yet FLDM is seeing strong revenue growth and holds core technologies that will allow them to play in new markets, driving value for years to come, says David Ferreiro, Executive Director and Senior Analyst at Oppenheimer & Co. Inc.
“Fluidigm is a different type of company; it’s more like a biotech. It has revenue right now that’s growing very strongly, but it’s still in that growth mode and hasn’t hit profitability. But they have some core technologies that really set them apart from rest of the market that are allowing them to play in some new markets like single cell analysis that no one else has,” Ferreiro said.
FOR MORE INFORMATION ABOUT THIS INTERVIEW CLICK HERE.
Fluidigm‘s unique assets will be a value driver for future years, Ferreiro says, making FLDM a solid, albeit untraditional, player in the genomic technology space, which itself is seeing robust growth.
“Genomic technologies, like the new sequencing technologies, namely next-generation sequencing, have recently really captured the imagination of investors. Aside from the fact that it’s been the fastest area of growth in the life science tools space, much faster than the broader market, but the potential application to clinical diagnostics and personalized medicine and personalized medicine strategies,” Ferreiro said.
ACE Limited (ACE) Grows Internationally and Sees Improving Domestic Conditions
June 10, 2013
Cardinal Health (CAH) Focuses on Core Hospital Supply Business, Grows Dividend
January 22, 2014
Celgene Corporation (CELG) Diversifies Revenue Stream, Sees $1.5 Billion Opportunity in Cancer Drug Abraxane
April 29, 2013
Wells Fargo & Company (WFC) Sees Revenue Growth and Expected Rising Stock Prices
February 06, 2013
Medidata Solutions Inc (MDSO) Sees Revenue Growth, Margin Improvement as a Provider of SaaS Clinical Tech Solutions
October 31, 2013
